Powered by OpenAIRE graph
Found an issue? Give us feedback


Narodowy Instytut Leków
1 Projects, page 1 of 1
  • Funder: European Commission Project Code: 101046941
    Overall Budget: 2,665,560 EURFunder Contribution: 2,665,560 EUR

    Many bacteria that cause infectious diseases develop resistance to not only the primary antibiotic treatments available in the clinic but also to drugs of last resort which often require long treatment periods and come with significant side effects. At the same time many promising lead compounds with high activity and wide therapeutic windows have failed to progress to clinical trials due to poor solubility, protein absorption or other difficulties in formulation (e.g. low drugability). LeadtoTreat proposes a new solution to these challenges by introduction of a platform for future infection treatment enabling targeted delivery of novel lead compounds with low drugability as well as synergistic combinations of antibiotics and potentiators in a nano-formulation. A novel dual targeting approach, with both direct targeting toward the pathogenic bacteria as well as to areas of inflammation will be employed. This platform technology will be demonstrated by converting a highly active, but insoluble and protein binding, novel compound into targeted nano-formulations for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections with proven in vivo and in vitro safety. Furthermore, LeadtoTreat aims to identify novel synergistic combinations of antibiotics and potentiators and convert these into highly active targeted nano-formulations for treatment of MRSA infections. LeadToTreat will have significant impact on the future treatment of microbial infections, by demonstrating a pathway to co-delivery of synergistic combination of existing antibiotics as well a path way to revitalize the huge library of abandoned low-drugability lead compounds. From an innovation perspective, it is expected to also develop broadly applicable targeting tools (for MRSA, and roadmap for other indications). The project will be managed by SINTEF (Norway) involving Narodowy Instytut Lekow (National Medicine Institute, NMI, Poland) and NanoTag Biotechnologies GmbH (NTB, Germany).


Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.